HIKMA PHARMACEUTICALS
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Subsidiary
- Established
- 1978-01-01
- Employees
- -
- Market Cap
- $5.8B
- Website
- http://www.hikma.com
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 173
- Registration Number
- NCT03454503
- Locations
- 🇪🇬
National Cancer Institute (NCI), Cairo, Egypt
Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 157
- Registration Number
- NCT03452501
- Locations
- 🇸🇦
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
🇸🇦King Saud Medical City, Riyadh, Saudi Arabia
🇸🇦King Abdulaziz University Hospital, Jeddah, Saudi Arabia
Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan
Completed
- Conditions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03348046
- Locations
- 🇯🇴
Prince Hamza Hospital, Amman, Jordan
🇯🇴Jordan University of Science and Technology- King Abdallah University Hospital, Irbid, Jordan
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
Completed
- Conditions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 91
- Registration Number
- NCT02977312
- Locations
- 🇯🇴
Al Bashir Hospital, Amman, Jordan
🇯🇴Jordan University Hospital, Amman, Jordan
🇯🇴King Hussein Cancer Center, Amman, Jordan
© Copyright 2024. All Rights Reserved by MedPath